Sun Pharma Q2 FY27 results showed a 36.36 per cent year-on-year decline in consolidated net profit to ₹1,988.53 crore, due to exceptional expenses linked to the proposed Organon acquisition and US litigation.
The pharmaceutical company had reported a consolidated net profit of ₹3,124.95 crore in the corresponding quarter last fiscal, according to its regulatory filing on Friday.
Consolidated revenue from operations increased 11.88 per cent to ₹16,198.71 crore in the September quarter from ₹14,478.31 crore a year earlier.
Sun Pharma’s India sales rise 17.3%
Formulation sales in India increased 17.3 per cent to ₹5,552.3 crore during the quarter. The domestic business accounted for 34.5 per cent of consolidated sales.
Global innovative medicines sales grew 6.9 per cent to approximately $356 million, contributing 21.1 per cent of total sales. Emerging markets accounted for 20.7 per cent of consolidated revenue.
During its post-results call, the company said growth in innovative medicines was driven by performance across the US and international markets. Key products included Ilumya, Ciqua and Odumzo.
Organon acquisition and US litigation weigh on profit
Sun Pharma reported approximately ₹1,269 crore in exceptional expenses during the quarter.
These included around ₹923 crore towards a settlement related to US generic-pricing antitrust litigation. Another ₹346 crore was associated with the proposed acquisition of Organon.
Total expenses increased to ₹12,287.83 crore from ₹10,780.62 crore in the year-ago quarter.
The company said the Organon acquisition remained on track for completion by early 2027, subject to the fulfilment of customary closing conditions. Management indicated that additional transaction-related costs could arise before the deal closes.
Sun Pharma expands innovative medicines portfolio
Managing Director Kirti Ganorkar said performance during the quarter was supported by growth in India, emerging markets and other international markets.
He highlighted the US approval of Ilumya for treating adults with active psoriatic arthritis.
The company also strengthened its cardiovascular portfolio through the licensing of lerodalcibep, a PCSK9 inhibitor, for markets outside the US and China.
Sun Pharma shares close higher
Shares of Sun Pharmaceutical Industries settled 0.87 per cent higher at ₹1,778.25 apiece on the BSE on Friday.
The stock ended higher despite the decline in quarterly profit, as the company reported growth in revenue and key domestic and international business segments.
